Tell a Colleague

Prescribing Information

About ANGIOMAX

Clinical Information

About PCI

Bleeding – a Predictor
of Mortality

About HIT/HITTS

Removal of the Femoral
Arterial Catheter

Search Clinical Trials

Coming Events

Sales Call Request

ANGIOMAX Key Events at:

Mode of Action Video

See a vivid demonstration of ANGIOMAX in action. Watch ANGIOMAX: Thrombin-Specific Inhibition for Preventing Thrombosis and Thrombin-Mediated Platelet Activation.

Search Clinical Trials

The following is a list of various clinical trial Web sites:

Clinical Trials.gov, a service of The National Institutes of Health developed by the National Library of Medicine: http://clinicaltrials.gov/
CenterWatch: http://www.centerwatch.com/patient/studies/area1.html
ClinicalTrials.com, for comprehensive information for current clinical trials being conducted nationwide: http://www.clinicaltrials.com

Studies registered on clinicaltrials.gov can be accessed via the relevant study drug or approved medicine on this Web site. Any new trial will be added within 21 days of its inception.

Safety Considerations

ANGIOMAX with provisional use of glycoprotein IIb/IIIa inhibitor is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), and in patients with or at risk for heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI. ANGIOMAX is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. ANGIOMAX is contraindicated in patients with active major bleeding or hypersensitivity to ANGIOMAX or its components. The most common (

10%) adverse events for ANGIOMAX were back pain, pain, nausea, headache, and hypotension. An unexplained fall in blood pressure or hematocrit, or any unexplained symptom, should lead to serious consideration of a hemorrhagic event and cessation of ANGIOMAX administration. Please see complete prescribing information.